S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.
Megan Othus,Hagop M. Kantarjian,Stephen H. Petersdorf,Farhad Ravandi,John E. Godwin,Jorge E. Cortes,Sherry Pierce,Harry P. Erba,Stefan Faderl,Frederick R. Appelbaum,Elihu H. Estey +10 more
TL;DR: Though the observations are limited to patients treated with intensive therapy at SWOG institutions and MDA, the decrease in TRM with time emphasizes the problem with historical controls and could be considered when selecting AML induction therapy.
Journal ArticleDOI
Rituximab in relapsed or refractory hairy cell leukemia
Deborah A. Thomas,Susan O'Brien,Carlos E. Bueso-Ramos,Stefan Faderl,Michael J. Keating,Francis J. Giles,Jorge E. Cortes,Hagop M. Kantarjian +7 more
TL;DR: Rituximab has significant activity and minimal toxicity in HCL and warrants further study, and should be explored further in H CL with regard to eradication of minimal residual disease and in combination with nucleoside analogs.
Journal ArticleDOI
Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Xavier Badoux,Michael J. Keating,Sijin Wen,William G. Wierda,Susan O'Brien,Stefan Faderl,Rachel L. Sargent,Jan A. Burger,Alessandra Ferrajoli +8 more
TL;DR: The combination of lenalidomide and rituximab is active in patients with recurrent CLL and warrants further investigation.
Journal ArticleDOI
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Stefan Faderl,Srdan Verstovsek,Jorge E. Cortes,Farhad Ravandi,Miloslav Beran,Guillermo Garcia-Manero,Alessandra Ferrajoli,Zeev Estrov,Susan O'Brien,Charles Koller,Francis J. Giles,William G. Wierda,Monica Kwari,Hagop M. Kantarjian +13 more
TL;DR: Clofarabine plus cytarabine has activity in adult AML, achieving a good CR rate, however, survival does not appear to be improved compared with other regimens, and modifications of this combination in AML therapy of older patients warrant further evaluation.
Journal ArticleDOI
Cause of death in patients with lower-risk myelodysplastic syndrome.
Farshid Dayyani,Anthony P. Conley,Sara S. Strom,William Stevenson,Jorge E. Cortes,Gautam Borthakur,Stefan Faderl,Susan O'Brien,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia-Manero +10 more
TL;DR: The authors have recently shown that a majority of patients with myelodysplastic syndrome classified by the International Prognostic Scoring System as lower risk die without transformation to acute myelogenous leukemia (AML).